MU1210，25MG，SML2713-25MG，Sigma

Biochem/physiol Actions

ATP site-targeting, potent and selective inhibitor against cdc-like kinase (cdc2-like kinase) CLK1, CLK2, CLK4, and homeodomain-interacting protein kinase 2 (HIPK2), but not CLK3.
MU1210 is a potent and selective inhibitor against cdc-like kinase (cdc2-like kinase) CLK1, CLK2, CLK4 (CLK1/2/4 IC₅₀ = 8/20/12 nM; CLK1/2/4 K_i = 84/91/23 nM by NanoBRET) and HIPK2 (IC₅₀ = 29 nM) with good selectivity over HIPK1/3 (IC₅₀ = 187/159 nM), DYRK1a/1b/2 (IC₅₀ = 213/956/1309 nM), CLK3 (IC₅₀ >3 μM) and 194 other kinases. MU1210 enhances alternative spliced MDM4-S mRNA (10 μM, 24 h) and exhibits antiproliferation activity in MCF7 cultures (IC₅₀ in 72 h = 1.1 μM). Unlike most ATP site-targeting kinase inhibitors, X-ray crystallography shows that MU1210 is anchored to the back pocket instead of the hinge region of CLK1. MU140 serves as a negative control.